Tides CDMO Services
With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.
100+
Customers
30+
Projects (IND/P1/P2/P3/NDA)
150+
Scientists
Our Services
Peptides
Linear Peptides (＜50 aa)
Cyclic Peptides (＜50 aa)
Peptide Modifications
Key RSMs and Intermediates
Oligonucleotides
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Drug Delivery Materials
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Linear Peptides (＜50 aa)
Cyclic Peptides (＜50 aa)
Peptide Modifications
Key RSMs and Intermediates
Molecular Type
- Linear Peptides (<50 aa)
- Cyclic Peptides (<50 aa)
- Arginine-rich Peptides
- Stapled Peptides
- Peptide Modifications: PEG, lipidation, N-methylation, etc.
- Key RSMs and Intermediates
- ADC Drug-Linker and PDC (OEB 5)
Technology
- Solid/Liquid/Hybrid Strategies Synthetic Solutions
- Combinate Downstream Technologies with Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Pre-formulation Development
- Comprehensive Analysis and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- Full Time Employee (FTE)
- Fee for Service (FFS)
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Molecular Type
- 16~100 mer Oligonucleotides and Derivatives
- Modified Nucleotides
- Oligonucleotide Conjugates
- Custom Monomer
- Custom Galnac Derivatives
Technology
- Solid Phase Oligonucleotide Synthesis Technology Platform
- Ion Exchange, Ultrafiltration, Freeze-drying, and Other Purification and Post-processing Technologies
- Nucleic Acid Modification and Routine Injection Preparation Research and Development Capability (Including LNP)
- Comprehensive Analysis and Quality Research
Service Scope
- mg to g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Manufacturing (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- FTE (Full-Time Equivalent)
- FFS (Fee for Service)
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Molecular Type
- Polymer-drug Conjugates, Dendrimers, Polypeptides
- Cationic/Ionizable Lipids, Peg-lipid, Phospholipids
- GalNAc Derivatives, Modified Monosaccharides, Synthetic Oligo[poly]saccharides
Technology
- Solid Phase and Liquid Phase Synthesis Technology Platform
- Combinate Downstream Technologies with prep-HPLC and Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Formulations Development and Manufacturing
- Comprehensive Analysis, Inspection and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP & GMP)
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
Porton Sites
Minhang, Shanghai
Area: 20,000 ㎡
For mg-kg Scale Preparation, Process Development and Quality Research
Fengxian, Shanghai
Area: 64,000 ㎡
IND, Clinical Batches and Commercial Manufacturing
Testing, Release and Stability Study
Beibei, Chongqing
GMP Production Lines for Liquid Injection, Lyophilized Powder and Oral Preparations
Liquid Injection: 30-60 M Bottles/year
Lyophilized Powder: 6-12 M/year
Pudong, Shanghai
Area: 5,000+ ㎡
Bioconjugation (10-200 L, OEB 5)
Injectable Drug Product Development and Manufacturing
Analytical Platforms
Pre-clinical to Phase II
Case Studies
More
Co-processing Series: 2. ASD - How Co-Processing can replace Spray Drying
With spray drying, a prevalent method for producing amorphous solid dispersions (ASD), the process involves rapidly drying a solution with hot gas, resulting in high energy consumption and significant infrastructure and operational costs.
More
Co-processing Series: 1. What is co-processing and how is the industry embracing it?
Co-processing enhances the flow and density properties of active pharmaceutical ingredients (API) thus simplifying oral solid formulation. In some cases, co-processing can be used to generate Amorphous Solid Dispersion and offers more expeditious alternatives to traditional methods such as spray drying, nano-milling, or hot-melt extrusion.
More
From R&D to Phase III: Peptide 39AA Project Completed in 10 Months
More
News
MoreNews2024-12-11
Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs
More
News2024-12-06
Porton Recognized as an Exemplary Case for Sustainable Development Among Chinese Listed Companies in 2024
More
News2024-12-06
Porton Pharma Solutions is thrilled to announce the launch of its newly redesigned official website
More
News2024-11-13
Porton Has Been Invited to the China–Slovenia Business and Investment Forum and Had a Friendly Meeting with Slovenian Officials.
More
News2024-11-09
Porton’s New Modality Capacity Upgrade Ceremony Successfully Held
More
News2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
More
